Loading
A simple score of how well a patient can get about and look after themselves: ECOG 0 is fully active, 1 restricted from strenuous work, 2 up more than half the day, 3 in bed more than half the day, 4 bedbound. It predicts how treatment will be tolerated and gates almost every trial.
Answer a few questions from a report and read the guideline statement that applies, quoted word for word with its source. Educational aids to prepare for an appointment, not advice.
The ECOG/WHO scale (0-5) and the Karnofsky scale (100-0) are the standard fitness measures in oncology. Most phase 3 trials enrol only ECOG 0-1, so evidence for the many patients with PS 2-3 is thin; 'fit' versus 'unfit' (for intensive chemotherapy, cisplatin, transplant) is often decided by performance status plus organ function and comorbidity, and phrases like 'cisplatin-ineligible' or 'transplant-ineligible' define whole treatment pathways. Geriatric assessment captures frailty more precisely than PS and changes treatment in older adults. Poor PS caused by the cancer itself can improve dramatically when an effective targeted drug works.
Showing the technology this term belongs to: Geriatric assessment.
Trifluridine-tipiracil with bevacizumab is the refractory-line standard, and a reminder that combining two drugs already on the shelf can beat anything new in the same line.
Trifluridine-tipiracil became the other refractory-line standard alongside regorafenib, and the backbone that SUNLIGHT later improved on by adding bevacizumab.
The deprivation gradient in lung cancer is not only about who gets the disease. Among people who already have it, and at the same stage, poorer patients are less likely to be offered the treatment that works.
The rule that a patient with a resected stage II or III lung cancer is offered chemotherapy and a patient with a small stage I tumour is not. Everything added to adjuvant treatment since has had to beat, or be added to, this 5 percent.
The first time a targeted biological agent extended survival in lung cancer, and the first time median survival in the advanced setting crossed twelve months. It also set the pattern that a drug's exclusion criteria can matter as much as its mechanism.
The ceiling of undirected cytotoxic chemotherapy, measured precisely. Everything that came afterwards, from histology-directed pemetrexed to EGFR inhibitors to checkpoint blockade, is an attempt to break a plateau this trial demonstrated could not be broken by changing the drugs.
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Geriatric assessment, Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV).
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.
Shares Cancer cachexia, Geriatric assessment, Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II).
Shares Relapsed and refractory classical Hodgkin lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Waldenström macroglobulinaemia.